beta(3)-Adrenoceptor antagonism improves clinical outcomes of chronic heart failure.
Chronic heart failure (CHF) is a leading cause of morbidity and mortality throughout the world. The pathogenesis of CHF is complex but beta(1)-adrenoceptors are critical in the process, because beta(1)-adrenoceptor blockers have been shown to significantly reduce the mortality and hospitalization rates in patients with CHF. Recent animal and human studies have demonstrated that there is an over expression of beta(3)-adrenoceptors in the failing heart, and stimulation of these receptors leads to further depression in ventricular function. We hypothesize that beta(3)-adrenoceptors and their over activities are one of the critical mechanisms of CHF, and addition to conventional heart failure therapies, beta(3)-adrenoceptor antagonism would further improve cardiac function and clinical outcomes.
Wu
Tongguo
T
Department of Cardiology, The Red Cross Hospital of Guangzhou City, The Fourth Affiliated Hospital of Jinan University, Guangzhou 510220, PR China. wutongguo@sohu.com
Wang
Lexin
L
D058673:Adrenergic beta-3 Receptor Antagonists; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D000818:Animals; D002303:Cardiac Output, Low / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*; D006321:Heart / Q000187:drug effects; D006801:Humans; D008955:Models, Cardiovascular; D009206:Myocardium / Q000378:metabolism*; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000209:etiology / Q000378:metabolism* / Q000517:prevention & control*
D058673:Adrenergic beta-3 Receptor Antagonists; D000319:Adrenergic beta-Antagonists